Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Gladding

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Journal of Cardiovascular Development and Disease|January 27, 2018
Advanced Electrocardiography Identifies Left Ventricular Systolic Dysfunction in Non-Ischemic Cardiomyopathy and Tracks Serial Change over TimeKerryanne Johnson, Stacey Neilson, Andrew To, et al.
JACC. Cardiovascular Interventions|November 21, 2009
Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation studyPatrick Gladding, Harvey White, Jamie Voss, et al.
JACC. Cardiovascular Interventions|October 24, 2009
Feasibility, safety, and efficacy of a novel polymeric pimecrolimus-eluting stent: traditional pre-clinical safety end points failed to predict 6-month clinical angiographic resultsJohn A Ormiston, Mark W I Webster, Robert S Schwartz, et al.
Plos One|March 31, 2017
ECG-derived spatial QRS-T angle is associated with ICD implantation, mortality and heart failure admissions in patients with LV systolic dysfunctionSarah Gleeson, Yi-Wen Liao, Clementina Dugo, et al.
JACC. Cardiovascular Interventions|May 26, 2009
The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trialPatrick Gladding, Mark Webster, Irene Zeng, et al.
JACC. Cardiovascular Interventions|May 26, 2009
The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trialPatrick Gladding, Mark Webster, Irene Zeng, et al.
European Heart Journal|August 7, 2019
Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie?Gregory J Wehner, Linyuan Jing, Christopher M Haggerty, et al.
Theranostics|September 11, 2013
Bioengineering silicon quantum dot theranostics using a network analysis of metabolomic and proteomic data in cardiac ischemiaFolarin Erogbogbo, Jasmine May, Mark Swihart, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Journal of Cardiovascular Development and Disease|January 27, 2018
Advanced Electrocardiography Identifies Left Ventricular Systolic Dysfunction in Non-Ischemic Cardiomyopathy and Tracks Serial Change over TimeKerryanne Johnson, Stacey Neilson, Andrew To, et al.
JACC. Cardiovascular Interventions|November 21, 2009
Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation studyPatrick Gladding, Harvey White, Jamie Voss, et al.
JACC. Cardiovascular Interventions|October 24, 2009
Feasibility, safety, and efficacy of a novel polymeric pimecrolimus-eluting stent: traditional pre-clinical safety end points failed to predict 6-month clinical angiographic resultsJohn A Ormiston, Mark W I Webster, Robert S Schwartz, et al.
Plos One|March 31, 2017
ECG-derived spatial QRS-T angle is associated with ICD implantation, mortality and heart failure admissions in patients with LV systolic dysfunctionSarah Gleeson, Yi-Wen Liao, Clementina Dugo, et al.
JACC. Cardiovascular Interventions|May 26, 2009
The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trialPatrick Gladding, Mark Webster, Irene Zeng, et al.
JACC. Cardiovascular Interventions|May 26, 2009
The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trialPatrick Gladding, Mark Webster, Irene Zeng, et al.
European Heart Journal|August 7, 2019
Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie?Gregory J Wehner, Linyuan Jing, Christopher M Haggerty, et al.
Theranostics|September 11, 2013
Bioengineering silicon quantum dot theranostics using a network analysis of metabolomic and proteomic data in cardiac ischemiaFolarin Erogbogbo, Jasmine May, Mark Swihart, et al.
Pageof 3